Vendor strategies in the global breast cancer liquid biopsy testing devices market

The global breast cancer liquid biopsy testing devices market is expected to grow at a CAGR of 23.56% during the forecast period. Some of the prominent vendors in the global breast cancer liquid biopsy testing devices market include Menarini Industrie Farmaceutiche Riunite Srl, Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Genomic Health Inc., Illumina Inc., Myriad Genetics Inc., Natera Inc., QIAGEN NV, and Thermo Fisher Scientific Inc., among others.

Vendors are focusing on strategies such as new product launches to enhance their position in the market. For instance, A. Menarini Industrie Farmaceutiche Riunite Srl, in November 2019, the company launched Target Selector pan-TRK assay, a liquid biopsy test for the detection of TRK proteins. Bio-Rad Laboratories Inc., in April 2019, the company received the US FDA approval for BioPlex 2200 Lyme Total Assay for the diagnosis of Lyme disease.

Request for: Free Sample Report

Similarly, F. Hoffmann-La Roche Ltd., in December 2019, the company received CE Mark approval for its Accu-Chek SugarView app. Illumina Inc., in June 2019, the company launched the expanded version of VeriSeq NIPT Solution v2, a next-generation sequencing (NGS) based approach to non-invasive prenatal testing (NIPT). Hence, the growing number of product launches is expected to spur the growth of the global breast cancer liquid biopsy testing devices market during the forecast period.